News & Updates

Show Multimedia Only

Aspirin does not cut death risk in hospitalized COVID-19 patients

20 Jan 2022 by

Adding aspirin to usual care did not lead to a reduced mortality rate in patients hospitalized with COVID-19, according to a study by the RECOVERY* Collaborative Group.

20 Jan 2022

Epstein-Barr virus may be the initial trigger for MS

20 Jan 2022 by

Epstein-Barr virus (EBV) may be the first trigger for the development of multiple sclerosis (MS) in most cases, says an expert.

20 Jan 2022

Sitafloxacin a promising treatment alternative for UTI

20 Jan 2022 by

Oral sitafloxacin was just as effective and safe as levofloxacin for the treatment of complicated and uncomplicated urinary tract infections (UTIs) in adults, according to a phase III study from China.

20 Jan 2022

DVT risk not raised after COVID-19 vaccination

19 Jan 2022 by

There is no apparent increased risk of deep vein thrombosis (DVT) following receipt of the COVID-19 vaccine, according to a study presented at ASH 2021.

19 Jan 2022

Early remdesivir treatment lowers risk of COVID-19 progression

19 Jan 2022 by

In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.

19 Jan 2022

CATALYST sparks signals favouring namilumab for COVID-19

19 Jan 2022 by

In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.

19 Jan 2022

Original New Drug Application Approvals by US FDA (01 - 15 January 2022)

19 Jan 2022

New drug applications approved by US FDA as of 01-15 January 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

19 Jan 2022

Percutaneous ethanol injection shrinks benign cystic thyroid nodules

19 Jan 2022

Treatment with percutaneous ethanol injection (PEI) appears to produce marked reductions in the volume of benign cystic thyroid nodules, with the reduction evident at 6 months post-treatment and stable over time, according to the results of a meta-analysis.

19 Jan 2022

Zuranolone for sleeplessness promising in early study

19 Jan 2022

The orally bioavailable, investigational neuroactive steroid zuranolone appears to be beneficial in the treatment of insomnia, producing improvements in sleep measures, including sleep efficiency, duration of awakenings, and total sleep time in adults, according to the results of a phase I study.

19 Jan 2022

Ibrutinib add-on to obinutuzumab sustains PFS benefit in CLL/SLL

19 Jan 2022 by

Adding ibrutinib to obinutuzumab in the first-line setting sustains progression-free survival (PFS) benefit in patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL), including patients with high-risk genomic features, according to the ﬁnal analysis of the iLLUMINATE* trial.

19 Jan 2022

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Aspirin does not cut death risk in hospitalized COVID-19 patients

Epstein-Barr virus may be the initial trigger for MS

Sitafloxacin a promising treatment alternative for UTI

DVT risk not raised after COVID-19 vaccination

Early remdesivir treatment lowers risk of COVID-19 progression

CATALYST sparks signals favouring namilumab for COVID-19

Original New Drug Application Approvals by US FDA (01 - 15 January 2022)

Percutaneous ethanol injection shrinks benign cystic thyroid nodules

Zuranolone for sleeplessness promising in early study

Ibrutinib add-on to obinutuzumab sustains PFS benefit in CLL/SLL